Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals

被引:7
|
作者
Martinez-Dubarbie, Francisco [1 ,2 ]
Guerra-Ruiz, Armando [3 ]
Lopez-Garcia, Sara [1 ,2 ]
Irure-Ventura, Juan [2 ,4 ]
Lage, Carmen [1 ,2 ,5 ]
Fernandez-Matarrubia, Marta [1 ,2 ]
Pozueta-Cantudo, Ana [1 ,2 ]
Garcia-Martinez, Maria [1 ,2 ]
Corrales-Pardo, Andrea [1 ,2 ,6 ]
Bravo, Maria [1 ,2 ]
Martin-Arroyo, Juan [1 ]
Infante, Jon [1 ,2 ,7 ,8 ]
Lopez-Hoyos, Marcos [2 ,4 ,9 ]
Garcia-Unzueta, Maria Teresa [2 ,3 ]
Sanchez-Juan, Pascual [7 ,10 ]
Rodriguez-Rodriguez, Eloy [1 ,2 ,7 ,8 ]
机构
[1] Marques de Valdecilla Univ Hosp, Neurol Serv, Santander 39008, Spain
[2] Inst Res Marques Valdecilla IDIVAL, Santander 39011, Spain
[3] Marques de Valdecilla Univ Hosp, Biochem & Clin Anal Dept, Santander 39008, Spain
[4] Marques de Valdecilla Univ Hosp, Immunol Dept, Santander 39008, Spain
[5] Univ Calif San Francisco, Global Brain Hlth Inst, Equ Brain Hlth, San Francisco, CA 94143 USA
[6] Univ Europea Atlantico, Hlth Sci Dept, Santander 39011, Spain
[7] Network Ctr Biomed Res Neurodegenerat Dis CIBERNED, Madrid 28220, Spain
[8] Univ Cantabria, Med & Psychiat Dept, Santander 39011, Spain
[9] Univ Cantabria, Mol Biol Dept, Santander 39011, Spain
[10] CIEN Fdn, Queen Sofia Fdn Alzheimer Ctr, Madrid 28220, Spain
关键词
Alzheimer's disease; plasma biomarkers; presymptomatic stages; comorbidities; amyloid; tau protein; ALZHEIMER-DISEASE; VALIDATION; BIOMARKERS;
D O I
10.3390/ijms25031481
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasma biomarkers for Alzheimer's disease (AD) are a promising tool that may help in early diagnosis. However, their levels may be influenced by physiological parameters and comorbidities that should be considered before they can be used at the population level. For this purpose, we assessed the influences of different comorbidities on AD plasma markers in 208 cognitively unimpaired subjects. We analyzed both plasma and cerebrospinal fluid levels of A beta 40, A beta 42, and p-tau181 using the fully automated Lumipulse platform. The relationships between the different plasma markers and physiological variables were studied using linear regression models. The mean differences in plasma markers according to comorbidity groups were also studied. The glomerular filtration rate showed an influence on plasma A beta 40 and A beta 42 levels but not on the A beta 42/A beta 40 ratio. The amyloid ratio was significantly lower in diabetic and hypertensive subjects, and the mean p-tau181 levels were higher in hypertensive subjects. The glomerular filtration rate may have an inverse relationship on plasma A beta 40 and A beta 42 levels but not on the amyloid ratio, suggesting that the latter is a more stable marker to use in the general population. Cardiovascular risk factors might have a long-term effect on the amyloid ratio and plasma levels of p-tau181.
引用
收藏
页数:17
相关论文
共 30 条
  • [1] Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform
    Martinez-Dubarbie, Francisco
    Guerra-Ruiz, Armando
    Lopez-Garcia, Sara
    Lage, Carmen
    Fernandez-Matarrubia, Marta
    Infante, Jon
    Pozueta-Cantudo, Ana
    Garcia-Martinez, Maria
    Corrales-Pardo, Andrea
    Bravo, Maria
    Lopez-Hoyos, Marcos
    Irure-Ventura, Juan
    Sanchez-Juan, Pascual
    Garcia-Unzueta, Maria Teresa
    Rodriguez-Rodriguez, Eloy
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [2] Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform
    Francisco Martínez-Dubarbie
    Armando Guerra-Ruiz
    Sara López-García
    Carmen Lage
    Marta Fernández-Matarrubia
    Jon Infante
    Ana Pozueta-Cantudo
    María García-Martínez
    Andrea Corrales-Pardo
    María Bravo
    Marcos López-Hoyos
    Juan Irure-Ventura
    Pascual Sánchez-Juan
    María Teresa García-Unzueta
    Eloy Rodríguez-Rodríguez
    Alzheimer's Research & Therapy, 15
  • [3] Relationship between baseline plasma p-tau181 and longitudinal changes in cognition and structural brain measures in a cohort of cognitively unimpaired older adults
    Pais, Marcos V.
    Kuo, Chia-Ling
    Ances, Beau M.
    Wetherell, Julie Loebach
    Lenze, Eric J.
    Diniz, Breno S.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2023, 15 (04)
  • [4] Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
    Volker Welge
    Oliver Fiege
    Piotr Lewczuk
    Brit Mollenhauer
    Hermann Esselmann
    Hans-Wolfgang Klafki
    Stefanie Wolf
    Claudia Trenkwalder
    Markus Otto
    Johannes Kornhuber
    Jens Wiltfang
    Mirko Bibl
    Journal of Neural Transmission, 2009, 116 : 203 - 212
  • [5] Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer's disease
    Welge, Volker
    Fiege, Oliver
    Lewczuk, Piotr
    Mollenhauer, Brit
    Esselmann, Hermann
    Klafki, Hans-Wolfgang
    Wolf, Stefanie
    Trenkwalder, Claudia
    Otto, Markus
    Kornhuber, Johannes
    Wiltfang, Jens
    Bibl, Mirko
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (02) : 203 - 212
  • [6] Plasma p-tau181/Aβ1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ1-42 and future cognitive decline
    Fowler, Christopher J.
    Stoops, Erik
    Rainey-Smith, Stephanie R.
    Vanmechelen, Eugeen
    Vanbrabant, Jeroen
    Dewit, Nele
    Mauroo, Kimberley
    Maruff, Paul
    Rowe, Christopher C.
    Fripp, Jurgen
    Li, Qiao-Xin
    Bourgeat, Pierrick
    Collins, Steven J.
    Martins, Ralph N.
    Masters, Colin L.
    Doecke, James D.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2022, 14 (01)
  • [7] Evaluation of serum NFL, T-tau, p-tau181, p-tau217, Aβ40 and Aβ42 for the diagnosis of neurodegenerative diseases
    Kahouadji, Samy
    Pereira, Bruno
    Sapin, Vincent
    Valentin, Audrey
    Bonnet, Agathe
    Dionet, Elsa
    Durif, Julie
    Lahaye, Clement
    Boisgard, Stephane
    Moisset, Xavier
    Bouvier, Damien
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2025, 63 (02) : 338 - 345
  • [8] CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
    Simren, Joel
    Brum, Wagner S.
    Ashton, Nicholas J.
    Benedet, Andrea L.
    Karikari, Thomas K.
    Kvartsberg, Hlin
    Sjons, Emma
    Lussier, Firoza Z.
    Chamoun, Mira
    Stevenson, Jenna
    Hopewell, Robert
    Pallen, Vanessa
    Ye, Keqiang
    Pascoal, Tharick A.
    Zetterberg, Henrik
    Rosa-Neto, Pedro
    Blennow, Kaj
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [9] Circulating medium- and long-chain acylcarnitines are associated with plasma P-tau181 in cognitively normal older adults
    Sharmin, Tahmida
    Chatterjee, Pratishtha
    Doecke, James D.
    Ashton, Nicholas J.
    Huynh, Kevin
    Pedrini, Steve
    Sohrabi, Hamid R.
    Heng, Benjamin
    Eslick, Shaun
    Zetterberg, Henrik
    Blennow, Kaj
    Garg, Manohar
    Martins, Ralph N.
    JOURNAL OF NEUROCHEMISTRY, 2025, 169 (02)
  • [10] Fully automatedmeasurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordancewith cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
    Bellomo, Giovanni
    Bayoumy, Sherif
    Megaro, Alfredo
    Toja, Andrea
    Nardi, Giovanna
    Gaetani, Lorenzo
    Blujdea, Elena R.
    Paoletti, Federico Paolini
    LidiaWojdala, Anna
    Chiasserini, Davide
    van der Flier, Wiesje M.
    Verberk, Ingem. W.
    Teunissen, Charlotte
    Parnetti, Lucilla
    ALZHEIMERS & DEMENTIA, 2024, 20 (04) : 2453 - 2468